Published by
@ShahidNShah
@ShahidNShah
Voraxaze® rapidly cleaves MTX into 2 inactive metabolites to provide a nonrenal pathway for elimination.
Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration in adult and pediatric patients with delayed methotrexate clearance due to impaired renal function. Voraxaze® is not recommended for use in patients who exhibit the expected clearance and expected plasma methotrexate concentration.
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Nov 14, 2024 at 11:39am